These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 22416774)

  • 1. EGFR/HER-targeted therapeutics in ovarian cancer.
    Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
    Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
    Sheng Q; Liu J
    Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER family inhibitors in pancreatic cancer: current status and future directions.
    Berz D; Miner T; McCormack E; Safran H
    Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
    Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
    Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
    Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
    Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.
    Hudson LG; Moss NM; Stack MS
    Future Oncol; 2009 Apr; 5(3):323-38. PubMed ID: 19374540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the ERBB family in cancer: couples therapy.
    Tebbutt N; Pedersen MW; Johns TG
    Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the HER-kinase axis in cancer.
    Gross ME; Shazer RL; Agus DB
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
    Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
    Wang Z; Fu S
    Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 19. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
    Flaherty KT; Brose MS
    Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging growth factor receptor antagonists for ovarian cancer treatment.
    Bonilla L; Oza A; Lheureux S
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):1-16. PubMed ID: 29528256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.